淀粉样蛋白和tau蛋白PET显像在痴呆中的临床研究进展  

Clinical research progress of amyloid and tau protein PET imaging in dementia

作　　者：张慧玮 左传涛 Zhang Huiwei;Zuo Chuantao(PET Center,Huashan Hospital,Fudan University)

机构地区：[1]复旦大学附属华山医院PET中心,上海200235

出　　处：《重庆医科大学学报》2021年第7期813-817,共5页Journal of Chongqing Medical University

基　　金：国家自然科学基金资助项目(编号:81901367、81971641)。

摘　　要：人口老龄化导致痴呆,特别是阿尔茨海默病(Alzheimer’s disease,AD)的发病率、患病率呈明显上升态势。正电子发射断层显像(positron emission tomography,PET)是近年来蓬勃发展的分子影像学诊断技术之一。在痴呆领域中,以神经病理学为基础,放射性标记的淀粉样蛋白和tau蛋白正电子显像剂可以客观地检测脑内异常蛋白沉积分布情况,可广泛应用于AD的早期诊断与鉴别诊断、疾病进展与预后评估等方面。本文主要针对淀粉样蛋白和tau蛋白正电子显像剂的发展和临床研究现状进行综述。The aging of the population has led to a significant increase in the incidence and prevalence rate of dementia,especially Alzheimer’s disease(AD).Positron emission tomography(PET)is one of the most advanced molecular imaging diagnostic techniques in recent years.In the field of dementia,based on neuropathology,radio-labeled molecular probes of amyloid and tau tracer can objectively detect the distribution of abnormal protein deposition in the brain,which can be widely used in the early diagnosis and differential diagnosis of AD,disease progression and prognosis assessment.This paper focuses on the development and clinical research status of molecular probes for amyloid and tau protein.

关 键 词：阿尔茨海默病 诊断 正电子显像剂 

分 类 号：R445.5[医药卫生—影像医学与核医学]